IMAAGEN: Phase 2 trial of abiraterone acetate plus prednisone for advanced prostate cancer | Dr Neal Shore at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides an update on IMAAGEN, a multicentre, open-label, single-arm, phase 2 trial evaluating the effect of abiraterone acetate plus prednisone on prostate specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer without radiographic evidence of metastatic disease.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews